Transactions

QOL Medical recapitalized by an investor group led by Cooper Capital

Nov. 2010

Client: QOL is a rare disease pharmaceutical company that markets Sucraid for the treatment of Congenital Sucrase-Isomaltase Disorder (CSID)

Role: Edgemont Partners acted as exclusive financial advisor to QOL Medical in its recapitalization by Cooper Capital

Location: Vero Beach, FL

Sector: Pharmaceutical Services

Lead Banker: David Blume

View Press Release

QOL medical logo

recapitalized by an investor group led by

cooper capital logo
Get In Touch